Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Unfortunately, we don't support Internet Explorer anymore as it has been replaced by Microsoft Edge. Please try using Edge or an alternative modern browser for the best experience.
Learn
Share
Network
Benefit
Delivering Affordable Innovation Through Global Partnerships
Chief Executive Officer
Emmes
Peter Ronco is Chief Executive Officer of Emmes. Earlier he Janssen/J&J global head of development responsible for leading the Global Development organization in delivering the Janssen drug development portfolio on time, within budget, and with robust quality while continuously improving to optimize efficiency and the patient and investigator experience in our studies. The Global Development organization harnesses the functional and geographic expertise across 40+ countries to bring insights into the shaping of our development programs to enable the correct development decision at the earliest timepoint in the most efficient manner. The Global Development organization has a globally distributed workforce of more than 9000 internal and external employees who are responsible for the operational execution of all Phase I – IV studies (including Medical Affairs programs) across all therapeutic areas and all geographic regions. They are accountable for identifying and implementing innovative clinical trial approaches and technologies that meet the current and future needs of our portfolio while also shaping our environment to build for the future. Global Development is comprised of the following key functions: Global Clinical Operations, Portfolio Delivery Operations, Medical Affairs Operations, Statistics & Decision Sciences, Clinical Pharmacology & Pharmacometrics, Integrated Data Analytics & Reporting, Project Management Organization, Enabling Business Information Solutions and Business Operations.
Prior to joining Janssen in 2017, Peter was the Senior Vice President of Global Clinical Operations at Bristol Myers-Squibb where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations. He also serves on the TransCelerate Biopharmaceutical Board of Directors. Prior to joining BMS, Peter was a consultant with Accenture, focusing on post-merger integration of R&D organizations. He is a graduate of Nottingham University in the UK and lives in Chester, NJ.